Compounded GLP-1 drops or tablets vs injections: do the oral versions work?

Short answer: Mostly no — only one oral GLP‑1 has solid, regulated evidence (Rybelsus/semaglutide). “Compounded” GLP‑1 drops or tablets from compounding pharmacies are unapproved, usually untested, and often unreliable in dose, stability and absorption. Injectable, approved GLP‑1 (e.g., Wegovy/Ozempic for semaglutide; Mounjaro for tirzepatide) gives predictable, proven effects.

Key points

• Approved oral option: Rybelsus (semaglutide tablet) is FDA‑approved for type 2 diabetes and has clinical trial data showing it works when taken exactly as directed. Rybelsus uses a specific absorption enhancer and formulation to get a tiny peptide through the gut.
• Why most compounded oral products usually don’t work: GLP‑1 peptides are fragile and poorly absorbed by the gut. Rybelsus’s efficacy depends on a specific drug formulation (and dosing instructions). Compounded “drops”/tablets typically lack that validated formulation and absorption agent, so they may deliver little or none of the active drug to the bloodstream.
• Safety and quality risks with compounded products: no FDA approval or routine clinical‑trial proof, variable potency, contamination risk, instability, inaccurate labels, and uncertain sterility. That raises risks for underdosing (no benefit) or unknown side effects.
• Injectables are proven and reliable: approved injectables (semaglutide brands Ozempic for diabetes and Wegovy for weight loss; tirzepatide brand Mounjaro for diabetes) have large clinical-trial data showing consistent blood levels and significant effects on blood sugar and weight. Injections avoid the absorption problems oral peptides face.
• Side effects and monitoring: regardless of form, GLP‑1 drugs can cause nausea, vomiting, gallbladder problems, pancreatitis risk, and interactions with other diabetes drugs. Approved products come with labeled safety monitoring and guidance; compounded products lack that oversight.

Recommendations

• Use FDA‑approved products prescribed by a clinician. If you want an oral GLP‑1, discuss Rybelsus (semaglutide) with your doctor — it’s the only oral GLP‑1 with robust trial data and a validated formulation.
• For stronger weight‑loss effects, discuss injectable options (Wegovy, Ozempic, or Mounjaro depending on diagnosis and availability) with your provider — these are more potent and predictable than oral semaglutide.
• Avoid compounded GLP‑1 drops/tablets. If cost or access is the concern, ask your prescriber about manufacturer patient‑assistance programs, generic availability, insurance options, or legitimate telemedicine clinics that prescribe FDA‑approved products.
• If you’re already using compounded product, stop and talk to your clinician about switching to an approved medication and appropriate medical monitoring.

If you want, tell me: are you considering these for diabetes or weight loss, and are cost/insurance or needle aversion the main issues? I can outline specific FDA‑approved options and ways to access them.